News | April 27, 2026
Nihilent unveils nSEPIA Beta to turn emotional wellness into measurable science
nSEPIA aims to bring structure to an area long dominated by subjectivity
nSEPIA aims to bring structure to an area long dominated by subjectivity
The move brings one of the country’s most widely prescribed blood thinners onto Cost Plus Drug Company’s online pharmacy platform
The first Phase III and second Phase III trials will be multi-centre, randomised, assessor-blind, active-comparator studies to determine the efficacy, safety and tolerability of orally administered Zintrodiazine
Founded by Amit Patni, the company rolls out 90+ formulations across acute and specialty therapies
At IIT Roorkee’s Vision 2047 conference, the union minister highlights BioE3 policy, rising biotech startups, and major scientific milestones
Multidisciplinary team expansion brings integrated medical, surgical, and radiation oncology services under one roof
The Pharmaceuticals portfolio and pipeline are more promising than perhaps ever before
The investigational therapy, MDX2003, is designed to go after cancer cells with a multi-pronged immune attack
The study evaluated oral semaglutide in young patients with type 2 diabetes and found it delivered a superior reduction in HbA1c
Aims to boost speed & precision in patient care
Subscribe To Our Newsletter & Stay Updated
